In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae
- 31 January 2012
- journal article
- research article
- Published by Elsevier BV in International Journal of Antimicrobial Agents
- Vol. 39 (1), 86-89
- https://doi.org/10.1016/j.ijantimicag.2011.09.012
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-Producing EnterobacteriaceaeAntimicrobial Agents and Chemotherapy, 2011
- In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermentersJournal of Antimicrobial Chemotherapy, 2010
- Spread of OXA-48-Encoding Plasmid in Turkey and BeyondAntimicrobial Agents and Chemotherapy, 2010
- Diversity, Epidemiology, and Genetics of Class D β-LactamasesAntimicrobial Agents and Chemotherapy, 2010
- In Vitro Activity of NXL104 in Combination with β-Lactams against Klebsiella pneumoniae Isolates Producing KPC CarbapenemasesAntimicrobial Agents and Chemotherapy, 2009
- Spread of OXA-48-Positive Carbapenem-Resistant Klebsiella pneumoniae Isolates in Istanbul, TurkeyAntimicrobial Agents and Chemotherapy, 2008
- Dissemination of CTX-M-15 β-Lactamase Genes Carried on Inc FI and FII Plasmids among Clinical Isolates of Escherichia coli in a University Hospital in Istanbul, TurkeyJournal of Clinical Microbiology, 2008
- Carbapenem-Hydrolyzing Oxacillinase, OXA-48, Persists in Klebsiella pneumoniae in Istanbul, TurkeyChemotherapy, 2008
- PER-1- and OXA-10-like β-lactamases in ceftazidime-resistant Pseudomonas aeruginosa isolates from intensive care unit patients in Istanbul, TurkeyClinical Microbiology & Infection, 2005
- A new plasmidic cefotaximase in a clinical isolate of Escherichia coliInfection, 1990